Atlas Trials

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Clinical trial NCT04849364 · TERMINATED

Trial details

NCT number
NCT04849364
Sponsor
Bryan Schneider, MD
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerTriple Negative Breast Cancer
Start date
2021-08-24
Primary completion
2024-10-24
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.